The need and challenges for development of an Epstein-Barr virus vaccine
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases
This publication has 18 references indexed in Scilit:
- Behavioral, Virologic, and Immunologic Factors Associated With Acquisition and Severity of Primary Epstein–Barr Virus Infection in University StudentsThe Journal of Infectious Diseases, 2012
- Epstein-Barr Virus: An Important Vaccine Target for Cancer PreventionScience Translational Medicine, 2011
- Soluble Rhesus Lymphocryptovirus gp350 Protects against Infection and Reduces Viral Loads in Animals that Become Infected with Virus after ChallengePLOS Pathogens, 2011
- Epstein‐Barr virus and gastric carcinomaPathology International, 2010
- Phase I Trial of a CD8+T-Cell Peptide Epitope-Based Vaccine for Infectious MononucleosisJournal of Virology, 2008
- Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young AdultsThe Journal of Infectious Diseases, 2007
- Sustained elevation of Epstein–Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinomaBritish Journal of Cancer, 2007
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006
- Characteristics of Hodgkin's Lymphoma after Infectious MononucleosisNew England Journal of Medicine, 2003
- Epstein–Barr Virus InfectionNew England Journal of Medicine, 2000